GHRP-6

It is like a prototype car from the 1980s that genuinely started and drove, proving the engine concept worked, but never passed safety testing or went into production. The manufacturer moved on to better models, and the only ones you can buy now are unofficial copies built in someone's garage, with no MOT and a sales sticker that says 'for display purposes only'.

Agonist at the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs and hypothalamic neurons. Activation of this Gq-coupled receptor triggers phospholipase C signalling, intracellular calcium release and exocytosis of stored growth hormone, amplified by synergy with GHRH and reduced somatostatin tone. A separate proposed pathway involves the CD36 scavenger receptor in non-pituitary tissues, implicated in its preclinical cytoprotective effects. Because it hits the ghrelin receptor it also stimulates appetite and can transiently nudge prolactin and cortisol.

Research contexts. Not proven uses, and not recommendations.

The one thing that is genuinely well established in humans is the core pharmacology: GHRP-6 reliably triggers a pulse of growth hormone release in healthy people, shown by Bowers and colleagues from the late 1980s onward, and it acts synergistically with GHRH. It has a short circulating half-life (on the order of tens of minutes). Beyond that, human evidence is thin. It was studied diagnostically and as a candidate to stimulate the GH axis, but it was never developed into a licensed product and was superseded by orally active secretagogues. The much-promoted cardioprotective and tissue-protective benefits come almost entirely from rodent and in-vitro studies (e.g. doxorubicin-cardiotoxicity models), not human outcome trials. There is no robust human evidence that it improves body composition, performance, recovery or longevity.

• !Not a licensed medicine: sold as an unlicensed 'research chemical' labelled 'not for human consumption', with no pharmaceutical quality control on identity, purity, sterility or endotoxin content.
• !Grey-market products may be underdosed, contaminated, mislabelled or non-sterile; injection of unsterile material carries infection risk.
• !Stimulates the ghrelin receptor, so it characteristically increases appetite; it can also transiently raise prolactin and cortisol, reducing selectivity versus newer secretagogues.
• !Sustained, non-pulsatile GH/IGF-1 elevation in general carries theoretical risks (insulin resistance, fluid retention, joint pain, carpal-tunnel-type symptoms) and unknown long-term effects from chronic unsupervised use.
• !Banned in competitive sport under the WADA Prohibited List (growth hormone secretagogues, class S2).
• !Modern marketing extrapolates animal cardioprotection/anti-ageing data to humans without supporting human trials. This is a major overclaim.

Not a licensed medicine in the UK. The MHRA has not authorised GHRP-6 for any indication, and it is not an approved or routinely available prescription product. It is an investigational/research substance. As a synthetic peptide intended to have a physiological effect it falls within the scope of the Human Medicines Regulations 2012, so supplying or selling it for human use without authorisation is unlawful; vendors sidestep this by labelling it a 'research chemical' or reagent 'not for human consumption'. There is no quality, safety or efficacy oversight of material sold on that basis. It is also prohibited in sport under UK Anti-Doping/WADA rules.

1. 01
   On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone — Bowers CY, Momany FA, Reynolds GA, Hong A, Endocrinology (1984)

   Original characterisation of the GHRP-6 hexapeptide as a specific GH secretagogue in vitro and in vivo.

2. 02
   Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone — Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO, Journal of Clinical Endocrinology & Metabolism (1990)

   Landmark human study demonstrating GHRP-6 releases GH in normal men and synergises with GHRH.

3. 03
   A receptor in pituitary and hypothalamus that functions in growth hormone release — Howard AD, Feighner SD, Cully DF, et al., Science (1996)

   Cloning of the growth hormone secretagogue receptor (GHS-R1a), the target of GHRP-6, predating discovery of its endogenous ligand ghrelin.

4. 04
   Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms — Berlanga-Acosta J, et al., Frontiers in Pharmacology (2024)

   Representative preclinical (rat) cardioprotection study illustrating that the cardioprotective claims remain animal-stage.